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Background: The direct effect of the coronavirus disease 2019 (COVID-19) pandemic
on patients with intestinal failure (IF) has not been described.
Methods:We conducted a nationwide study of UK IF centers to evaluate the infection
rates, presentations, and outcomes in patients with types 2 and 3 IF.
Results: A total of 45 patients with IF contracted COVID-19 between March and
August 2020; this included 26 of 2191 (1.2%) home parenteral nutrition (HPN)–
dependent adults and 19 of 298 (6.4%) adults hospitalized with type 2 IF. The propor-
tion of patients receiving nursing care forHPNadministrationwas higher in thosewith
community-acquired COVID-19 (66.7%) than the proportion in the entire HPN cohort
(26.1%; P< .01). TwoHPN-dependent and 1 hospitalized patient with type 2 IF died as
a direct consequence of the virus (6.7% of 45 patients with types 2 or 3 infected).
Conclusion: This is the first study to describe the outcomes of COVID-19 in a large
cohort of patients requiring long-termPN.Methods to reduce hospital and community
nosocomial spreadwould likely be beneficial.
KEYWORDS
COVID-19, home parenteral nutrition, intestinal failure, outcome
CLINICAL RELEVANCY STATEMENT
Atotal of 1.2%, 26of2191, adults dependentonhomeparenteral nutri-
tion and 6.4%, 19 of 298, hospitalized adults with acute severe intesti-
nal failure (IF) contracted coronavirus disease 2019 (COVID-19) dur-
ing the first wave of the pandemic in the UK. A total of 6.7% (3 of 45)
of adults with types 2 or 3 IF who were infected with COVID-19 dur-
ing the study period died as a direct result of viral infection. Meth-
ods to reduce hospital and community nosocomial spread would be
beneficial.
INTRODUCTION
Medical care delivery had to rapidly adapt to the coronavirus dis-
ease 2019 (COVID-19) pandemic while healthcare systems tried to
reduce morbidity and mortality in patients deemed to be at higher
risk of harm from infection. A recent international consensus posi-
tion paper highlighted the risk to patients with chronic intestinal fail-
ure (IF) who require home parenteral nutrition1 (HPN). (Chronic IF
that requires HPN is also known as “type 3 IF, see below.”2) As per
the European Society for Clinical Nutrition and Metabolism (ESPEN),
IF was categorized as follows:2 Type 1 is self-limiting while receiving
PN for <28 days (excluded from this study). Type 2 is severe acute IF,
metabolically unstable with enterocutaneous/enteroatmospheric fis-
tulas and/orhostile abdomen, andalso labeledhereas acute IF. Patients
with type 3 IF receive HPN, and type 3 IF may be a reversible (eg,
awaiting reconstructive surgery [reversible]) or irreversible condition.
A subsequent survey of healthcare professional experience described
the pandemic’s impact on care provision to these vulnerable patients.3
Indeed, in the UK, individuals deemed to be clinically extremely vul-
nerable from the infection, which included individuals with type 3 IF,
were advised to “shield”—that is, to stay at home andminimize all face-
to-face contact.4 However, there are no data published on the direct
impact of the COVID-19 pandemic on HPN-dependent patients or on
those hospitalized with acute severe (“type 2”2) IF. We therefore con-
ducted a nationwide study to evaluate the risk and outcomes posed by
COVID-19 on patients with types 2 and 3 IF.
METHODS
An audit proforma was circulated among UK adult and pediatric IF
centers. Data on both types 2 and 3 IF were collected from March
13, 2020, to August 1, 2020. The number of HPN-dependent patients
was recorded on March 13, 2020, to determine an at-risk population
at the start of the audit period. All patients with type 2 IF, defined as
index hospitalization with acute severe metabolically unstable IF and
PN requirement for>28 days, were included.2
Patients were diagnosed with COVID-19 if either of the following
weremet:
1. Positive nasopharyngeal polymerase chain reaction for severe
acute respiratory syndrome coronovirus 2 (SARS-CoV-2) or serum
IgG antibody testing
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TABLE 1 Demographics of adults infected with coronavirus disease 2019
Data set
Patients receiving HPN (type 3 IF) (N= 26) Patients with acute IF (type 2 IF) (N= 19)
N % N %
Age, years, mean± 95% confidence
interval
57.3± 6.6 NA 59.2± 6.9 NA
Female 19 73 9 47.4
White 24 92 17 89.4
South Asian 1 4 1 5.3
Black African 1 4 0 0
Chinese 0 0 1 5.3
Duration of PN at infection, mean±
95% confidence interval
28.0± 11.5months NA 84.4± 28.3 days NA
Abbreviations: HPN, home parenteral nutrition; IF, intestinal failure; NA, not applicable.
2. Swab/antibody results negative or untested, abnormal chest radi-
ology (chest x-ray or computed tomography scan), with or without
compatible symptoms (persistent cough, pyrexia [>37.5 ◦C], loss of
taste or smell)
Community-acquired infection was defined as a positive diagnosis
within 3 days of any hospital admission.5
As this study was a retrospective audit, ethical committee approval
was not required; however, participating centers were required to
register the study with the hospital audit department and submit




The audit was completed by 20 (of 26 invited [77%]) UK adult IF cen-
ters (included 2191 HPN-dependent patients); 515 (23.5%) were hos-
pitalized for IF- or non–IF-related reasons during the audit period.
The study also included 298 adults with acute severe (type 2) IF. Of
the 2191 HPN-dependent patients, 1254 (57.2%) self-administered
PN; otherwise, PN was administered by a home care nurse (n = 572
[26.1%]), family member/carer (n = 134 [6.1%]), combination of both a
nurse and a family member/carer (n = 203 [9.3%]), or unknown in 28
(1.3%) cases.
COVID-19 infection in HPN-dependent adults
A total of 26/2191 (1.2%) HPN-dependent adults were diagnosedwith
COVID-19 infection. Tables 1 and 2 provide demographics and comor-
bidities/immunosuppression of those infected with COVID-19. IF eti-
ology included cancer (n = 6), chemotherapy enteritis (n = 1), chronic
intestinal pseudo-obstruction (n = 1), Crohn’s disease (n = 2), mesen-
teric ischemia or volvulus (n = 9), surgical complications (n = 2), and
TABLE 2 Comorbidities of adults contracting coronavirus disease
2019 infection
Comorbidity
HPN (type 3 IF)
(n= 26)
Acute severe
(type 2) IF (n= 19)
Bodymass index>30 2 2
Diabetes mellitus type 2 1 3
Chronic heart disease 4 6
Cerebrovascular disease 1 1
Chronic neurological disease 2 1
Chronic respiratory disease 7 3
Chronic kidney disease 1 1
Nonhematological cancer 6 2
Hematological cancer 1 2
Liver disease 2 2
Immunosuppressive condition 1 0
Organ transplant 0 1
Abbreviations: HPN, home parenteral nutrition; IF, intestinal failure.
other (n = 5). The IF mechanism included short-bowel syndrome (n
= 14; 9 with jejunostomy, 3 with ileostomy/ileo-rectal anastomosis, 2
with colon in continuity), fistulas (n = 1), motility (n = 5), and obstruc-
tion (n= 6).
Table 3 shows the COVID-19 method of diagnosis and symptoms
experienced. A total of 21 of 26 patients were diagnosed with COVID-
19 in the community, 6 of whom remained at home whereas 15
required subsequent hospitalization (7 of the 15 to their local hos-
pital and 8 of the 15 to the IF center). The proportion of patients
receiving nursing care forHPNadministrationwas higher in thosewith
community-acquired COVID-19 (14/21 [66.7%]) than the proportion
in the entire HPN cohort (26.1%; χ2 P< .01).
Five of the 26 (19.2%) patients were diagnosed with hospital-
acquired COVID-19 3 days after hospital admission for IF- or non–
IF-related reasons, representing 1.0% (5/515) of the overall HPN-
dependent hospitalized cohort.
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Method of detection of
COVID-19 infection
Positive nasopharyngeal PCR swab alone 17 5 17
Positive antibody alone 0 0 0
Positive PCR swab and positive antibody 0 0 2




Unknown 1 0 0
COVID-19 symptoms Asymptomatic 3 0 4
Unknown 2 0 0
Pyrexia (>37.5 ◦C) 11 5 11
Loss of sense of smell/taste 0 0 4
Respiratory symptoms (see below) 13 4 11
Gastrointestinal (see below) 4 2 1
Other 1 1 1
Respiratory symptoms Upper respiratory tract symptoms 1 0 1
Lower respiratory tract symptoms 1 0 0
Shortness of breath 5 2 3
Cough 4 2 7
Hypoxia 3 1 1
Type 2 respiratory failure 1 1 0
Gastrointestinal
symptoms
Vomiting 3 1 0
Abdominal pain 1 0 0
Stoma/fistula output increase 2 1 1
Immunosuppression Adalimumab 1 0 0




Tacrolimus 0 0 1
Azathioprine 0 0 1
Abbreviations: COVID-19, coronavirus disease 2019; HPN, home parenteral nutrition; IF, intestinal failure; PCR, polymerase chain reaction.
Notably, gastrointestinal (GI) symptoms associated with COVID-19
infection including vomiting in 4 patients and increased stoma output
in 3 patients.
Treatment and outcomes of HPN-dependent patients
infected with COVID-19
Of the 15 patients with community-acquired COVID-19 who were
then hospitalized, antibiotics were administered to 8 and hydroxy-
chloroquine or dexamethasone to 2. Although only 1 patient required
ventilation and recovered, 2 other nonventilated patients died at
admission day 1 and 2 died from COVID-19 infection (Table 4); thus,
13 patients survived, with a mean admission of 12.4 ± 6.7 days. Of
the 6 community-treated patients, 3 died at 38.3± 10.8 days following
COVID-19 infection, all from underlying cancer unrelated to COVID-
19 infection. Of the 5 patients who were diagnosed with COVID-19
while in the hospital, none required ventilation, dexamethasone, or
remdesivir. Four patients were discharged after 70.5 ± 82.1 days fol-
lowing COVID-19; 1 remained in the hospital at the end of the audit
period (61 days). An unrelated death occurred after discharge at 115
days following COVID-19 infection. The fatality rate of patients with
type 3 IF among the entire HPN population was 0.09% (2/2191); the
case fatality rate was 7.7% (2/26).
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TABLE 4 Cause of deaths






death, days Cause of death

























HPN5 Female White British 75 Malignancy (primary
unknown)
48 Progressivemalignancy




AIF3 Female White British 72 Hematological
malignancy
21 Progressivemalignancy





Abbreviations: AIF, acute IF; COVID-19, coronavirus disease 2019; IF, intestinal failure; HPN, home parenteral nutrition; IFALD, IF-associated liver disease.
COVID-19 infections in patients with type 2 IF
A total of 19 of 298 (6.4%) patients with type 2 IF were diagnosed
with COVID-19 infection in 12 centers. Tables 1 and 2 provide demo-
graphics and comorbidities/immunosuppression of those infectedwith
COVID-19. The IF etiology included adhesions (n = 2), cancer (n = 3),
mesenteric ischemia (n = 3), surgical complications (n = 7), trauma (n
= 1), and other (n = 3). The IF mechanism included short-bowel syn-
drome (n= 10; 9 to jejunostomy and 1 to ileostomy/ileo-rectal anasto-
mosis), fistulas (n = 6), motility or mechanical obstruction (n = 2), and
mucosal disease (n=1).Method ofCOVID-19 diagnosis and symptoms
are outlined in Table 3. Notably, GI symptoms associated with COVID-
19 infection included increased stoma output in 1 patient.
Treatment and outcomes of patients with type 2 IF
infected with COVID-19
On contracting COVID-19, 10 of 19 patients were transferred from
the IF ward within the same hospital to a designated COVID-19 gen-
eralward, and1 patientwas transferred to an infectious diseasesward;
8 patients remained on the IF ward. No patient required ventilation.
A total of 14 of the 19 patients received antibiotics, but no patient
received dexamethasone or remdesivir. Two of those with type 2 IF
died, 1 (1/298 = 0.3%; the case fatality rate was 5.3% [1/19]) within 7
days of COVID-19 infection and 1 in a hospice with progressive malig-
nancy21days afterCOVID-19 infection (seeTable4 for details). A total
of 14were discharged home; 3 patients remained in the hospital at the
audit period’s end.
Pediatric results
Four (out of 18 invited [22%]) UK pediatric centers completed the
audit, representing 73 HPN-dependent children. A total of 37 of the
73 (50.7%) required hospitalization during the audit period. Nine chil-
dren with type 2 IF were also included. The family/carer provided PN
administration for 68 of the 73 (93.2%) patients. Only a single 7-year
old White British boy with chronic intestinal pseudo-obstruction and
no additional comorbidity was diagnosed with COVID-19. A relative
administered his PN over 84 months prior to COVID-19 infection.
He developed pyrexia, upper respiratory tract infection, and increased
stoma output, requiring admission for 3 days to his local hospital owing
to COVID-19 infection. He recovered fully.
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F IGURE 1 Flowchart of outcomes for adult HPN and acute IF infections. COVID-19, coronavirus disease 2019; HPN, home parenteral
nutrition, IF, intestinal failure
DISCUSSION
This is the first paper to describe occurrence and outcomes of
patients with types 2 and 3 IF infected with COVID-19. Twenty-
one of 2191 (1.2%) HPN-dependent adults acquired COVID-19 while
living at home, 2 of whom (0.1% of whole cohort) died from the
infection. Nineteen of 298 (6.4%) adults with type 2 IF acquired
COVID-19 while in the hospital, 1 of whom (0.35% of whole cohort)
died from the infection. Of the 45 patients with types 2 and 3 IF
infected with COVID-19 in this study, 3 (6.7%) died from the infection.
The infection rate for the UK population was 0.5% (305,760 cases in
the UK population, ∼66,000,000 by August 1, 2020), and the UK case
fatality rate was 18.6% (56,990 deaths recorded in 305,760 individu-
als with a positive test result) on August 1, 2020.6,7 Patients with IF
presented with typical symptoms suggestive of COVID-19, which can
include GI symptoms;8 clinicians caring for patients with IF should be
vigilant specifically for changes in stoma output as a possible indicator
of infection (Figure 1).
HPN-dependent patients acquired COVID-19 while living in the
community despite being asked to “shield.”4 Patients may have con-
tracted COVID-19 at home from any close contact, although it is
noteworthy that a significantly higher proportion of those who con-
tracted the infection at home required nursing care for HPN adminis-
tration (66.7% compared with 26.1% in the overall cohort). Access to
appropriate personal protective equipment has been reported by some
to have been challenging for those caring for HPN patients.3 Noso-
comial spread of COVID-19 has been noted in hospitalized patients,
particularly those with invasive devices (odds ratio reported as 4.28,
P = .007).9 A number of IF services have endeavored to rapidly train
patients or familymembers during the pandemic to reduce nursing ser-
vice pressure and minimize contact, and this strategy may be useful
during the continued pandemic.1
As with any retrospective study, data capture may be limited. In
addition, we restricted the data collected so as not to overburden
busy clinical teams during the pandemic and therefore primarily col-
lected more detailed information on those patients acquiring COVID-
19; future, larger studies evaluating the impact of additional risk fac-
tors including comorbidities and underlying disease/IF mechanism on
COVID-19 infection rates and outcomes compared with the overall
HPN population, as well as factors implicated in hospital and com-
munity nosocomial spread, would be beneficial. Nonetheless, we have
reported the largest series to date of occurrence and outcomes in an
extremely vulnerable group of patients with severe types 2 and 3 IF.
Nosocomial infection while at home may be a concern in those requir-
ing nursing care for HPN administration, although larger international
data sets with contact testing and tracing are required, not only in the
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